Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial

Movement Disorders

Volumn 25, Issue 16, 2010, Pages 2724-2727

  Ondo, William G ^a   Shinawi, Lina ^a   Moore, Steven ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Fluctuating; Levodopa; Orally dissolved levodopa; Parkinson's disease; Stride length; Timed tapping

Indexed keywords

CARBIDOPA PLUS LEVODOPA; PLACEBO;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG SOLUBILITY; GAIT; HAND MOVEMENT; HUMAN; MALE; MORNING DOSAGE; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNIFIED PARKINSON DISEASE RATING SCALE;

ADMINISTRATION, ORAL; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GAIT; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 78650203588     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23158     Document Type: Article

References (9)

1. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring carbidopa/levodopa. Ann Neurol 1996; 39: 37-45.
2. Blanchet PJ, Allard P, Gregoire L, et al. Risk factors for peak dose dyskinesia in 100 carbidopa/levodopa treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189-193.
3. Schrag A, Ben-Shlomo Y, Brown R, et al. Young onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998; 13: 885-894.
4. Parcopa. Data on file UCB Pharma.
5. Nausieda P, Pfeiffer R, Tagliati M, et al. A multi-center, open label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther 2005; 27: 58-63.
6. Fahn E, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. New York: Macmillan; 1987, 153-163.
7. Langston JW, Widner H, Goetz C, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
8. Moore ST, MacDougall H, Gracies J-M, Cohen H, Ondo W. Long-term monitoring of gait in Parkinson's disease. Gait Posture 2007; 26: 200-207.
9. Moore ST, MacDougall H, Gracies J-M, Ondo W. Locomotor response to levodopa in fluctuating Parkinson's disease. Exp Brain Res 2008; 184: 469-478.